|
India's largest drugmaker, Ranbaxy, has been granted an exclusive six-month marketing opportunity to sell a generic version of Japanese drugmaker Eisai's drug for Alzheimer's in the US. The US drug regulator, the Food and Drug Adminisration (FDA) upheld the exclusivity status after it dismissed Israeli drugmake Teva's claim for a shared marketing exclusivity for the drug. The Indian drug maker is likely to get the final approval from the US regulator, to market the drug under its brand name Aricept, on expiry of the patent protection on 25 November. According to industry analysts, the drug has the potential to fetch the company around $300 million during the exclusivity period. Ranbaxy is yet to disclose the facility from which it will produce the drug for marketing in the US. Two of its manufacturing plants are yet not approved by the FDA for supply to that country. Ranbaxy shares shot 5.6 per cent on the Bombay Stock Exchange to close at Rs561.95 today, the highest they have touched this year.
|
